Halozyme Therapeutics HALO Preferred Stock, Shares Authorized
Preferred Stock, Shares Authorized at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's preferred stock, shares authorized.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's preferred stock, shares authorized?
- Halozyme Therapeutics (HALO) reported preferred stock, shares authorized of $20M in Q1 2026.
- How has Halozyme Therapeutics's preferred stock, shares authorized changed year-over-year?
- Halozyme Therapeutics's preferred stock, shares authorized decreased by 0.0% year-over-year, from $20M to $20M.
- What is the long-term trend for Halozyme Therapeutics's preferred stock, shares authorized?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's preferred stock, shares authorized has grown at a 0.0% compound annual growth rate (CAGR), from $20M to $20M.